For following the competition: what moved in each program, several studies read as one move.
- Autologous Anti-CD19 CAR-T Cells CABA-201
- mezagitamab
- Immunoglobulins, Intravenous
- + 57 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Autoimmune Diseases to watchlistEvery Monday by email · turn it off any timePro · free during the beta